학술논문

Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; NOV 1 2019, 37 31, 2p. Supplement: S
Subject
Language
English
ISSN
15277755